Bővebb ismertető
As a new trend in antitumour drug research a series of terminal bifunctional sugar alkohols had been developed in the i95oies. The development of these compounds was based on the principle of two effective formulas.
The first concept was based on "mustard nitrogen" structure in which 2-chloro^thylamino molecule part is carrying the biological function. Vargha, L. et al. (1955) linked the 2-chloro-ethylamino group to sugar alkohols in the 1,6 position as to a skeleton molecule. The most widely used compound of this series is Degranol^ i,6-di-(2-chloroethylamino)-i,6-dideoxy-D-mannitol.
According to the other concept the molecular structure itself is carrying the biological function. This theory led to the synthesis of Myleran, 1,4-dimethane sulfonyloxy-butane, described by A. Haddow in 1953. By substituting the alkane chain with D-mannitol 1,6-dimethane sulfo-nyl-D-mannitol (Mannogranol) was synthetized almost at the same time by Haddow, A. et al. (1958) and Vargha, L. (1959), respectively.
Pharmacological studies proved that Degranol inhibits lymphopoiesis like nitrogen mustard, while mannitol-mylerane myelopoiesis as the myleranes.
Institóris, L. and Horváth, I. P. (i960, 1961, 1964, 1967) examined the halogenic derivatives of sugar alko-hols-especially the alpha, omega-bromine substituted compounds-with the aim to find compounds with selective myelotropic effect. According to their theory the
9